Other
Journal
About P&T Journal
Contacts:Editor:
ssherritze@medimedia.com
Advertising:
mliberti@medimedia.com
Circulation:
lgardineer@medimedia.com
Production:
wpeart@medimedia.com
Rate Card
Production Specifications
Statement of Purpose
Guidelines for Authors
Masthead
Editorial Board
Reprints
Recent Issues
January 2013
Features
Deaths From Contaminated Methylprednisolone Highlight Failures of Compounding Pharmacies
Less Hospital Access to Outside Vendors and More Visits From State Pharmacy Boards
To avoid more fatalities and cases of fungal meningitis, as occurred from contaminated steroid products made at the New England Compounding Center, hospitals and their pharmacy directors must stay abreast of future changes in state and federal laws regarding compounding.
Stephen Barlas
Current Diagnosis and Treatment of Anxiety Disorders
The authors review the challenges in diagnosis; the roles of stress, neurotransmitters, and biological factors; cognitive–behavior therapy; and pharmacological and nonpharmacological strategies in patients with anxiety.
Alexander Bystritsky, MD, PhD; Sahib S. Khalsa, MD, PhD; Michael E. Cameron, PhD; and Jason Schiffman, MD, MA, MBA
Novel Oral Anticoagulants for Venous Thromboembolism Prophylaxis After Total Hip or Knee Replacement
An Update on Rivaroxaban (Xarelto)
Novel anticoagulants represent promising alternatives to the traditional anticoagulants for VTE prophylaxis following hip and knee replacement surgery. Preliminary analyses for rivaroxaban suggest that it may be cost-effective and cost-saving in these patients.
Zachary Stacy, PharmD, BCPS
Meeting Highlights
American Heart Association Scientific Sessions 2012
American Association for the Study of Liver Disease
American College of Rheumatology/Association of Rheumatology Health Professionals
Topics include serelaxin, aspirin alone, and aspirin combinations for cardiovascular disease; sovaprevir and pegylated interferon/ribavirin combinations for hepatitis C; apremilast and ustekinumab for psoriatic arthritis; and a newly approved drug, tofacitinib, for rheumatoid arthritis.
Walter Alexander
Departments
Medication Errors
Oral Syringes: Making Better Use of a Crucial And Economical Risk-Reduction Strategy
Using a parenteral syringe to prepare or give oral or enteral liquids can be deadly.
Matthew Grissinger, RPh, FASCP
Prescription: Washington
Pharmacies Cannot Directly Bill Medicare For Compounded Drugs Sent to Physicians
Pharmacies can no longer bill Medicare directly for compounded drugs that they supply to physicians.
Stephen Barlas
New Drugs/Drug News/New Medical Devices
FDA approvals, drug indications, and updates
Pharmaceutical Approval Update
Tofacitinib (Xeljanz) for rheumatoid arthritis, perampanel (Fycompa) for partial-onset seizures, and teriflunomide (Aubagio) for relapsing multiple sclerosis
Marvin M. Goldenberg, PhD, RPh, MS
Drug Forecast
Abiraterone (Zytiga), a Novel Agent for the Management of Castration-Resistant Prostate Cancer
Abiraterone (Zytiga) for castration-resistant prostate cancer
Tamara Goldberg, PharmD, BCPS; and Evangelina Berrios-Colon, PharmD, MPH, BCPS, CACP
